Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 6.8% – Still a Buy?

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) rose 6.8% on Friday . The company traded as high as $2.45 and last traded at $2.4450. Approximately 619,623 shares changed hands during trading, a decline of 77% from the average session volume of 2,678,377 shares. The stock had previously closed at $2.29.

Wall Street Analyst Weigh In

LXRX has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, June 18th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Lexicon Pharmaceuticals in a report on Monday, March 23rd. Finally, Citigroup raised their price objective on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the company a “buy” rating in a research note on Monday, May 11th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $4.55.

Lexicon Pharmaceuticals Trading Up 5.0%

The firm has a market cap of $1.07 billion, a PE ratio of -34.35 and a beta of 1.07. The company has a debt-to-equity ratio of 0.24, a current ratio of 18.80 and a quick ratio of 18.77. The business has a 50-day moving average price of $1.98 and a two-hundred day moving average price of $1.62.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.00) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.04. The business had revenue of $21.10 million for the quarter, compared to analyst estimates of $9.79 million. Lexicon Pharmaceuticals had a negative net margin of 37.46% and a negative return on equity of 18.64%. Analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.17 EPS for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Large investors have recently bought and sold shares of the stock. UBS Group AG boosted its stake in shares of Lexicon Pharmaceuticals by 752.1% during the fourth quarter. UBS Group AG now owns 3,007,237 shares of the biopharmaceutical company’s stock valued at $3,458,000 after acquiring an additional 2,654,315 shares during the last quarter. Ishara Investments LP purchased a new position in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $1,012,000. Leonteq Securities AG purchased a new position in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $34,000. R Squared Ltd boosted its position in Lexicon Pharmaceuticals by 45.3% during the fourth quarter. R Squared Ltd now owns 46,579 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 14,530 shares during the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in Lexicon Pharmaceuticals in the 1st quarter worth approximately $1,170,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.